rs a robust and user-friendlyworkstation platform that views and reconstructs data in 2D/3D forvirtually any organ in the body. V3D-Calcium Scoring aids physicians indetermining the amount of calcified plaque accumulation in the coronaryarteries. V3D-Vascular is breakthrough software that permits rapidsegmentation and visualization of complex arterial structures using 3Dvolume rendering max
Date:10/4/2007
rs a robust and user-friendly
workstation platform that views and reconstructs data in 2D/3D for
virtually any organ in the body. V3D-Calcium Scoring aids physicians in
determining the amount of calcified plaque accumulation in the coronary
arteries. V3D-Vascular is breakthrough software that permits rapid
segmentation and visualization of complex arterial structures using 3D
volume rendering, maximum intensity projection and simulated x-ray views.
Viatronix, through application of the V3D technology, is developing
additional innovative products that will be useful in early detection of
other diseases, treatment planning, intervention, and follow-up evaluation.
Viatronix, Inc. is located in Stony Brook, NY. For further information,
call toll free 1-866-887-4636 or log on to:
http://www.viatronix.com
'/>"/>SOURCE Viatronix Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
Neurologix Announces Publication of Landmark Gene Therapy Study
Demonstrating Safety and Statistically Significant Improvement in
Patients With Advanced Parkinsons Disease2.
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions3.
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits4.
Landmark Study Published in the New England Journal of Medicine
Shows Important Benefits of Eprodisate (KIACTA) Treatment for
Patients with Amyloid A (AA) Amyloidosis5.
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study6.
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study7.
Landmark Findings From ECLIPSE Program Show Improved Control of
Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery8.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer9.
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs10.
Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results11.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis